11:35 AM EST - Merus Labs International Inc. : announced that it has completed the acquisition of the North American product rights for FACTIVE® (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc. Cornerstone recorded FACTIVE® 320mg tablet net sales of approximately $6.3 million U.S. in the United States for 2011. The Product has not been commercialized in Canada. Merus Labs International Inc.
shares T.MSL are trading up $0.18 at $1.72.
